Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 62

1.

A Radiolabeled Fully Human Antibody to Human Aspartyl (Asparaginyl) β-Hydroxylase Is a Promising Agent for Imaging and Therapy of Metastatic Breast Cancer.

Revskaya E, Jiang Z, Morgenstern A, Bruchertseifer F, Sesay M, Walker S, Fuller S, Lebowitz MS, Gravekamp C, Ghanbari HA, Dadachova E.

Cancer Biother Radiopharm. 2017 Mar;32(2):57-65. doi: 10.1089/cbr.2016.2141.

PMID:
28301261
2.

Targeting Prostate Cancer Stem Cells with Alpha-Particle Therapy.

Ceder J, Elgqvist J.

Front Oncol. 2017 Jan 9;6:273. doi: 10.3389/fonc.2016.00273. eCollection 2016.

3.

Establishment of the In Vivo Efficacy of Pretargeted Radioimmunotherapy Utilizing Inverse Electron Demand Diels-Alder Click Chemistry.

Houghton JL, Membreno R, Abdel-Atti D, Cunanan KM, Carlin S, Scholz WW, Zanzonico PB, Lewis JS, Zeglis BM.

Mol Cancer Ther. 2017 Jan;16(1):124-133. doi: 10.1158/1535-7163.MCT-16-0503. Epub 2016 Nov 9.

PMID:
28062708
4.

Targeted alpha therapy using short-lived alpha-particles and the promise of nanobodies as targeting vehicle.

Dekempeneer Y, Keyaerts M, Krasniqi A, Puttemans J, Muyldermans S, Lahoutte T, D'huyvetter M, Devoogdt N.

Expert Opin Biol Ther. 2016 Aug;16(8):1035-47. doi: 10.1080/14712598.2016.1185412. Epub 2016 May 19.

5.

Long-Term Toxicity of 213Bi-Labelled BSA in Mice.

Dorso L, Bigot-Corbel E, Abadie J, Diab M, Gouard S, Bruchertseifer F, Morgenstern A, Maurel C, Chérel M, Davodeau F.

PLoS One. 2016 Mar 16;11(3):e0151330. doi: 10.1371/journal.pone.0151330. eCollection 2016.

6.

A fully human antibody to gp41 selectively eliminates HIV-infected cells that transmigrated across a model human blood brain barrier.

McFarren A, Lopez L, Williams DW, Veenstra M, Bryan RA, Goldsmith A, Morgenstern A, Bruchertseifer F, Zolla-Pazner S, Gorny MK, Eugenin EA, Berman JW, Dadachova E.

AIDS. 2016 Feb 20;30(4):563-72. doi: 10.1097/QAD.0000000000000968.

7.

Single-Dose Anti-CD138 Radioimmunotherapy: Bismuth-213 is More Efficient than Lutetium-177 for Treatment of Multiple Myeloma in a Preclinical Model.

Fichou N, Gouard S, Maurel C, Barbet J, Ferrer L, Morgenstern A, Bruchertseifer F, Faivre-Chauvet A, Bigot-Corbel E, Davodeau F, Gaschet J, Chérel M.

Front Med (Lausanne). 2015 Nov 4;2:76. doi: 10.3389/fmed.2015.00076. eCollection 2015.

8.

Anti-CD45 radioimmunotherapy without TBI before transplantation facilitates persistent haploidentical donor engraftment.

Orozco JJ, Kenoyer A, Balkin ER, Gooley TA, Hamlin DK, Wilbur DS, Hylarides MD, Frost SH, Mawad R, O'Donnell P, Sandmaier BM, Fuchs EJ, Luznik L, Green DJ, Gopal AK, Press OW, Pagel JM.

Blood. 2016 Jan 21;127(3):352-9. doi: 10.1182/blood-2014-12-617019. Epub 2015 Nov 17.

9.

Quantitative single-particle digital autoradiography with α-particle emitters for targeted radionuclide therapy using the iQID camera.

Miller BW, Frost SH, Frayo SL, Kenoyer AL, Santos E, Jones JC, Green DJ, Hamlin DK, Wilbur DS, Fisher DR, Orozco JJ, Press OW, Pagel JM, Sandmaier BM.

Med Phys. 2015 Jul;42(7):4094-105. doi: 10.1118/1.4921997.

10.

A Critical Review of Alpha Radionuclide Therapy-How to Deal with Recoiling Daughters?

de Kruijff RM, Wolterbeek HT, Denkova AG.

Pharmaceuticals (Basel). 2015 Jun 10;8(2):321-36. doi: 10.3390/ph8020321. Review.

11.

Radioimmunotherapy of human tumours.

Larson SM, Carrasquillo JA, Cheung NK, Press OW.

Nat Rev Cancer. 2015 Jun;15(6):347-60. doi: 10.1038/nrc3925. Review. Erratum in: Nat Rev Cancer. 2015 Aug;15(8):509.

12.

Pushing the envelope-nonmyeloablative and reduced intensity preparative regimens for allogeneic hematopoietic transplantation.

Pingali SR, Champlin RE.

Bone Marrow Transplant. 2015 Sep;50(9):1157-67. doi: 10.1038/bmt.2015.61. Epub 2015 May 18. Review.

13.

(211)Astatine-Conjugated Monoclonal CD45 Antibody-Based Nonmyeloablative Conditioning for Stem Cell Gene Therapy.

Burtner CR, Chandrasekaran D, Santos EB, Beard BC, Adair JE, Hamlin DK, Wilbur DS, Sandmaier BM, Kiem HP.

Hum Gene Ther. 2015 Jun;26(6):399-406. doi: 10.1089/hum.2015.021.

14.

Tumor immunotargeting using innovative radionuclides.

Kraeber-Bodéré F, Rousseau C, Bodet-Milin C, Mathieu C, Guérard F, Frampas E, Carlier T, Chouin N, Haddad F, Chatal JF, Faivre-Chauvet A, Chérel M, Barbet J.

Int J Mol Sci. 2015 Feb 11;16(2):3932-54. doi: 10.3390/ijms16023932. Review.

15.

The elements of life and medicines.

Chellan P, Sadler PJ.

Philos Trans A Math Phys Eng Sci. 2015 Mar 13;373(2037). pii: 20140182. doi: 10.1098/rsta.2014.0182.

16.

α-Radioimmunotherapy with ²¹³Bi-anti-CD38 immunoconjugates is effective in a mouse model of human multiple myeloma.

Teiluf K, Seidl C, Blechert B, Gaertner FC, Gilbertz KP, Fernandez V, Bassermann F, Endell J, Boxhammer R, Leclair S, Vallon M, Aichler M, Feuchtinger A, Bruchertseifer F, Morgenstern A, Essler M.

Oncotarget. 2015 Mar 10;6(7):4692-703.

17.

Systemic targeted alpha radiotherapy for cancer.

Allen B.

J Biomed Phys Eng. 2013 Sep 17;3(3):67-80. eCollection 2013 Sep. Review.

18.

Targeted alpha anticancer therapies: update and future prospects.

Allen BJ, Huang CY, Clarke RA.

Biologics. 2014 Nov 10;8:255-67. doi: 10.2147/BTT.S29947. eCollection 2014. Review.

19.

Radioimmunotherapy: a specific treatment protocol for cancer by cytotoxic radioisotopes conjugated to antibodies.

Kawashima H.

ScientificWorldJournal. 2014;2014:492061. doi: 10.1155/2014/492061. Epub 2014 Oct 14. Review.

20.

²¹³Bi-DOTATOC receptor-targeted alpha-radionuclide therapy induces remission in neuroendocrine tumours refractory to beta radiation: a first-in-human experience.

Kratochwil C, Giesel FL, Bruchertseifer F, Mier W, Apostolidis C, Boll R, Murphy K, Haberkorn U, Morgenstern A.

Eur J Nucl Med Mol Imaging. 2014 Nov;41(11):2106-19. doi: 10.1007/s00259-014-2857-9. Epub 2014 Jul 29.

Supplemental Content

Support Center